2Twelves CJ. Oral idarubicin in solid tumor chemotherapy. Clin Drug Inverst,1995,9(Suppl 2):39. 被引量：1
3Avvisati G, Mandelli F, Petti MC, et al. Idarubicin (4 demethoxydaunorubicin) as a single agent for remission induction of previously untreated acute promyelocytic leukemia:a pilot study of the Italian Cooperative Group GIMEMA.Eur J Haematol,1990,44:257. 被引量：1
4Berman E, Heller G, Santorsa JA, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood,1991,77:1666. 被引量：1
5Carella AM, Carlier P, Pungolino E, et al, Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory of rapidly relapsed patients with acute myeloid leukemia, Leukemia,1993,7:196. 被引量：1
3Chauvenet AR,Madin P,Devidas M,et al.Antimetabolite therapy for lesser risk B-lineage acute lymphoblastic leukemia of childhood:a report from children′s oncology group study P9201[J].Blood,2007,110(8):1105-1111. 被引量：1
4Kamps WA,Veerman AJ,Van Wering ER,et al.Long-term follow-up of dutch childhood leukemia study group(DCLSG)protocols for children with acute lymphoblastic leukemia,1984-1991[J].Leukemia,2000,14(12):2240-2246. 被引量：1
7Schrappe M,Reiter A,Zimmermann M,et al.Long-term results of four consecutive trials in childhood aLL performed by the aLL BFM study group from 1981 to 1995[J].Leukemia,2000,14:2205 2222. 被引量：1
8Moricke A,Reiter A,Zimmermann M,et al.Risk adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival:treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL BFM 95[J].Blood,2008,111(9):4477-4489. 被引量：1
